CD8A and neoplasm: Inhibition of USP7 activates the p38 MAPK pathway, reprogramming M2 macrophages to M1, increasing CD8+ T cell infiltration, and reducing PD-L1 expression in tumor cells, thereby strengthening anti-tumor immune responses (190).